Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 11, 2015, Pages 2039-2049

  Nigam, Sanjay K ^a,b,c   Wu, Wei ^a   Bush, Kevin T ^b   Hoenig, Melanie P ^e   Blantz, Roland C ^b,d   Bhatnagar, Vibha ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; AMPHOLYTE; ARISTOLOCHIC ACID; BREAST CANCER RESISTANCE PROTEIN; CARNITINE; DIGOXIN; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; OCHRATOXIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2; PENICILLIN DERIVATIVE; PROBENECID; QUINIDINE; UREMIC TOXIN; DRUG;

AEROBIC METABOLISM; AGING; ARTICLE; CELL STRESS; DRUG ELIMINATION; DRUG TRANSPORT; EMBRYO DEVELOPMENT; GLUCONEOGENESIS; GLUCURONIDATION; GLYCOLYSIS; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; NONHUMAN; PHARMACOGENOMICS; REMOTE SENSING; SIGNAL TRANSDUCTION; CLASSIFICATION; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; UREMIA;

BIOLOGICAL TRANSPORT; HUMANS; KIDNEY TUBULES, PROXIMAL; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION; UREMIA;

EID: 84946733480     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02440314     Document Type: Article

References (113)

1. Nigam SK: What do drug transporters really do? Nat Rev Drug Discov 14: 29-44, 2015
2. Burckhardt G: Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 136: 106-130, 2012
3. Nigam SK, Bhatnagar V: How much do we know about drug handling by SLC and ABC drug transporters in children? Clin Pharmacol Ther 94: 27-29, 2013
4. Nigam SK, Bush KT, Bhatnagar V: Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Clin Pract Nephrol 3: 443-448, 2007
5. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: Discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos 31: 1-71, 2010
6. Ahn SY, Bhatnagar V: Update on the molecular physiology of organic anion transporters. Curr Opin Nephrol Hypertens 17: 499-505, 2008
7. Nigam SK, Bush KT, Martovetsky G, Ahn SY, Liu HC, Richard E, Bhatnagar V, Wu W: The organic anion transporter (OAT) family: A systems biology perspective. Physiol Rev 95: 83-123, 2015
8. Wu W, Jamshidi N, Eraly SA, Liu HC, Bush KT, Palsson BO, Nigam SK: Multispecific drug transporter Slc22a8 (Oat3) regulates multiple metabolic and signaling pathways. Drug Metab Dispos 41: 1825-1834, 2013
9. Martovetsky G, Tee JB, Nigam SK: Hepatocyte nuclear factors 4a and 1a regulate kidney developmental expression of drug-metabolizing enzymes and drug transporters. Mol Pharmacol 84: 808-823, 2013
10. Masereeuw R, Russel FG: Regulatory pathways for ATP-binding cassette transport proteins in kidney proximal tubules. AAPS J 14: 883-894, 2012
11. You G, Morris ME: Overview of drug transporter families. In: Drug Transporters: Molecular Characterization and Role in Drug Disposition, 2nd Ed., edited by You G, Morris ME, Hoboken, NJ, John Wiley & Sons, Inc., 2014, pp 1-6
12. Bush KT, Nagle M, Truong DM, Bhatnagar V, Kaler G, Eraly SA, Wu W, Nigam SK: Organic anion transporters. In: Drug Transporters: Molecular Characterization and Role in Drug Disposition, 2nd Ed., edited by You G, Morris ME, Hoboken, NJ, John Wiley & Sons, Inc., 2014, pp 25-42
13. Koepsell H: The SLC22 family with transporters of organic cations, anions and zwitterions. Mol AspectsMed 34: 413-435, 2013
14. Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK: Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem 281: 5072-5083, 2006
15. Lopez-Nieto CE, You G, Bush KT, Barros EJ, Beier DR, Nigam SK: Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney. J Biol Chem 272: 6471-6478, 1997
16. Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem 272: 30088-30095, 1997
17. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM: Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53: 503-529, 2013
18. Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita K, Kanai Y, Endou H: Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. J Am Soc Nephrol 16: 3498-3506, 2005
19. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372: 549-552, 1994
20. Simonson GD, Vincent AC, Roberg KJ, Huang Y, Iwanij V: Molecular cloning and characterization of a novel liver-specific transport protein. J Cell Sci 107: 1065-1072, 1994
21. Burckhardt G, Burckhardt BC: In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. In:Drug Transporters., edited by Fromm MF, Kim RB, Berlin, Heidelberg, Springer, 2011, pp 29-104
22. You G: Membrane transporters in drug disposition. Pharm Res 25: 441-443, 2008
23. Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK: The molecular pharmacology of organic anion transporters: From DNA to FDA? Mol Pharmacol 65: 479-487, 2004
24. Saito H: Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: Pharmacological and toxicological implications. Pharmacol Ther 125: 79-91, 2010
25. Sweet DH, Bush KT, Nigam SK: The organic anion transporter family: From physiology to ontogeny and the clinic. Am J Physiol Renal Physiol 281: F197-F205, 2001
26. Wang L, Sweet DH: Renal organic anion transporters (SLC22 family): Expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J 15: 53-69, 2013
27. Lee SC, Zhang L, Huang SM: Regulatory science perspectives on transporter studies in drug development. In: Drug Transporters: Molecular Characterization and Role in Drug Disposition, 2n Ed, edited by You G, Morris ME, Hoboken, NJ, John Wiley & Sons, 2014, pp 473-487
28. U.S. Food and Drug Administration: Guidance for Industry: Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Rockville, MD, U.S. Food and Drug Administration, Drug-Drug Interaction Working Group, Center for Drug Evaluation and Research (CDER), 2012, pp 1-75
29. Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A: Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 18: 1101-1108, 2012
30. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, Sugiyama Y: Prediction of fluoroquinolone-induced elevation in serum creatinine levels: A case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 89: 81-88, 2011
31. Motohashi H, Inui K: Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol Aspects Med 34: 661-668, 2013
32. Ahn SY, Eraly SA, Tsigelny I, Nigam SK: Interaction of organic cations with organic anion transporters. J Biol Chem 284: 31422-31430, 2009
33. Vallon V, Eraly SA, Rao SR, Gerasimova M, Rose M, Nagle M, Anzai N, Smith T, Sharma K, Nigam SK, Rieg T: A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol 302: F1293-F1299, 2012
34. Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, Murray BP, Bannister R, Cihlar T, Huang Y, Ray AS: Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 86: 350-357, 2014
35. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW: In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41: 353-361, 2013
36. Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH: Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Mol Pharmacol 85: 520-530, 2014
37. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722, 2009
38. Brady KP, Dushkin H, Förnzler D, Koike T, Magner F, Her H, Gullans S, Segre GV, Green RM, Beier DR: A novel putative transporter maps to the osteosclerosis (oc) mutation and is not expressed in the oc mutant mouse. Genomics 56: 254-261, 1999
39. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK: Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 294: F867-F873, 2008
40. Vanwert AL, Bailey RM, SweetDH: Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol 293: F1332-F1341, 2007
41. Nagle MA, Truong DM, Dnyanmote AV, Ahn SY, Eraly SA, Wu W, Nigam SK: Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem 286: 243-251, 2011
42. Truong DM, Kaler G, Khandelwal A, Swaan PW, Nigam SK: Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J Biol Chem 283: 8654-8663, 2008
43. Bekersky I, Popick AC: Disposition of bumetanide in the isolated perfused rat kidney: effects of probenecid and dose response. Am J Cardiol 57: 33A-37A, 1986
44. Tucker BJ, Blantz RC: Effect of furosemide administration on glomerular and tubular dynamics in the rat. Kidney Int 26: 112-121, 1984
45. Burnell JM, Kirby WM: Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations. J Clin Invest 30: 697-700, 1951
46. Lesi_nski J, Dzierzanowska D, Szymczak M, Linda H, Wiśniewska C, Nawara A, Winogrodzka A: Treatment of gonorrhoea with procaine penicillin plus probenecid. Br J Vener Dis 49: 358-361, 1973
47. Robbins N, Koch SE, Tranter M, Rubinstein J: The history and future of probenecid. Cardiovasc Toxicol 12: 1-9, 2012
48. Aslamkhan AG, Han YH, Yang XP, Zalups RK, Pritchard JB: Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin-Darby canine kidney cells. Mol Pharmacol 63: 590-596, 2003
49. DiGiusto G, Anzai N, Ruiz ML, Endou H, Torres AM: Expression and function of Oat1 and Oat3 in rat kidney exposed to mercuric chloride. Arch Toxicol 83: 887-897, 2009
50. Engström K, Ameer S, Bernaudat L, Drasch G, Baeuml J, Skerfving S, Bose-O’Reilly S, Broberg K: Polymorphisms in genes encoding potential mercury transporters and urine mercury concentrations in populations exposed to mercury vapor from gold mining. Environ Health Perspect 121: 85-91, 2013
51. Zalups RK, Ahmad S: Homocysteine and the renal epithelial transport and toxicity of inorganic mercury: Role of basolateral transporter organic anion transporter 1. J Am Soc Nephrol 15: 2023-2031, 2004
52. Torres AM, Dnyanmote AV, Bush KT, Wu W, Nigam SK: Deletion of multispecific organic anion transporter Oat1/Slc22a6 protects against mercury-induced kidney injury. J Biol Chem 286: 26391-26395, 2011
53. Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H: Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology 264: 74-79, 2009
54. Stefanovi_c V, Polenakovi_c M: Fifty years of research in Balkan endemic nephropathy: Where are we now? Nephron Clin Pract 112: c51-c56, 2009
55. Balachandran P, Wei F, Lin RC, Khan IA, Pasco DS: Structure activity relationships of aristolochic acid analogues: Toxicity in cultured renal epithelial cells. Kidney Int 67: 1797-1805, 2005
56. Nakagawa H, Hirata T, Terada T, Jutabha P, Miura D, Harada KH, Inoue K, Anzai N, Endou H, Inui K, Kanai Y, Koizumi A: Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid. Basic Clin Pharmacol Toxicol 103: 1-8, 2008
57. Toyohara T, Akiyama Y, Suzuki T, Takeuchi Y, Mishima E, Tanemoto M, Momose A, Toki N, Sato H, Nakayama M, Hozawa A, Tsuji I, Ito S, Soga T, Abe T: Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 33: 944-952, 2010
58. Vanholder R, Abou-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, DeDeyn PP, Drüeke TB, Fliser D, Glorieux G, Herget-Rosenthal S, Hörl WH, Jankowski J, Jörres A, Massy ZA, Mischak H, Perna AF, Rodriguez-Portillo JM, Spasovski G, Stegmayr BG, Stenvinkel P, Thornalley PJ, Wanner C, Wiecek A: The role of EUTox in uremic toxin research. Semin Dial 22: 323-328, 2009
59. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 23: 1211-1221, 2008
60. Vitetta L, Linnane AW, Gobe GC: From the gastrointestinal tract (GIT) to the kidneys: Live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins (Basel) 5: 2042-2057, 2013
61. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK: Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 10: 2842-2851, 2011
62. Masereeuw R, Mutsaers HA, Toyohara T, Abe T, Jhawar S, Sweet DH, Lowenstein J: The kidney and uremic toxin removal: Glomerulus or tubule? Semin Nephrol 34: 191-208, 2014
63. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku HO, Takeuchi Y, Mishima E, Abe M, Tanemoto M, Masuda S, Kawano H, Maemura K, Nakayama M, Sato H, Mikkaichi T, Yamaguchi H, Fukui S, Fukumoto Y, Shimokawa H, Inui K, Terasaki T, Goto J, Ito S, Hishinuma T, Rubera I, Tauc M, Fujii-Kuriyama Y, Yabuuchi H, Moriyama Y, Soga T, Abe T: SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 20: 2546-2555, 2009
64. Reyes M, Benet LZ: Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci 100: 3831-3842, 2011
65. Wu W, Dnyanmote AV, Nigam SK: Remote communication through solute carriers and ATP binding cassette drug transporter pathways: An update on the remote sensing and signaling hypothesis. Mol Pharmacol 79: 795-805, 2011
66. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G: Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106: 3698-3703, 2009
67. Ahn SY, Jamshidi N, Mo ML, Wu W, Eraly SA, Dnyanmote A, Bush KT, Gallegos TF, Sweet DH, Palsson BO, Nigam SK: Linkage of organic anion transporter-1 to metabolic pathways through integrated “omics”-driven network and functional analysis. J Biol Chem286: 31522-31531, 2011
68. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, Barshop BA, Nigam SK: Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 33: 180-192, 2008
69. Ahn SY, Nigam SK: Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis. Mol Pharmacol 76: 481-490, 2009
70. Mori K, Ogawa Y, Ebihara K, Aoki T, Tamura N, Sugawara A, Kuwahara T, Ozaki S, Mukoyama M, Tashiro K, Tanaka I, Nakao K: Kidney-specific expression of a novel mouse organic cation transporter-like protein. FEBS Lett 417: 371-374, 1997
71. Sakurai H: Urate transporters in the genomic era. Curr Opin Nephrol Hypertens 22: 545-550, 2013
72. Mount DB: The kidney in hyperuricemia and gout. Curr Opin Nephrol Hypertens 22: 216-223, 2013
73. Sautin YY, Johnson RJ: Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27: 608-619, 2008
74. Eraly SA, Hamilton BA, Nigam SK: Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun 300: 333-342, 2003
75. Gallegos TF, Martovetsky G, Kouznetsova V, Bush KT, Nigam SK: Organic anion and cation SLC22 “drug” transporter (Oat1, Oat3, andOct1) regulation during development and maturation of the kidney proximal tubule. PLoS One 7: e40796, 2012
76. Maeda A, Tsuruoka S, Kanai Y, Endou H, Saito K, Miyamoto E, Fujimura A: Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol 596: 166-172, 2008
77. Eraly SA, Blantz RC, Bhatnagar V, Nigam SK: Novel aspects of renal organic anion transporters. Curr Opin Nephrol Hypertens 12: 551-558, 2003
78. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99: 552-557, 1999
79. Nigam SK, Burton ME, Vasko MR: Quinidine-induced digoxin toxicity after discontinuing digoxin in a patient with renal failure. Clin Pharm 3: 662-664, 1984
80. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium: Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236, 2010
81. Kouznetsova VL, Tsigelny IF, Nagle MA, Nigam SK: Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1). Bioorg Med Chem 19: 3320-3340, 2011
82. Bhatnagar V, Xu G, Hamilton BA, Truong DM, Eraly SA, Wu W, Nigam SK: Analyses of 59 regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). J Hum Genet 51: 575-580, 2006
83. Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK: Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int 68: 1491-1499, 2005
84. Choudhuri S, Klaassen CD: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25: 231-259, 2006
85. Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, Gow JM, Ha C, Ma B, Poon A, Johns SJ, Stryke D, Castro RA, Tahara H, Choi JH, Chen L, Picard N, Sjödin E, Roelofs MJ, Ferrin TE, Myers R, Kroetz DL, Kwok PY, Giacomini KM: Genetic variation in the proximal promoter of ABC and SLC superfamilies: Liver and kidney specific expression and promoter activity predict variation. PLoS One 4: e6942, 2009
86. Han YF, Fan XH, Wang XJ, Sun K, Xue H, Li WJ, Wang YB, Chen JZ, Zhen YS, Zhang WL, Zhou X, Hui R: Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. Am J Hypertens 24: 340-346, 2011
87. Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM: Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci 102: 3451-3457, 2013
88. Fujita T, Brown C, Carlson EJ, Taylor T, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Fujita K, Castro R, Chen CW, Lin ET, Brett CM, Burchard EG, Ferrin TE, Huang CC, Leabman MK, Giacomini KM: Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 15: 201-209, 2005
89. Lopez-Lopez E, Ballesteros J, Piñan MA, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P, Navajas A, Garcia-Orad A: Polymorphisms in the methotrexate transport pathway: A new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 23: 53-61, 2013
90. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM: Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19: 497-504, 2009
91. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, Beck-Nielsen H, Brøsen K: A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics 23: 526-534, 2013
92. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86: 396-402, 2009
93. Schreuder MF, Bueters RR, Huigen MC, Russel FG, Masereeuw R, van den Heuvel LP: Effect of drugs on renal development. Clin J Am Soc Nephrol 6: 212-217, 2011
94. Pavlova A, Sakurai H, Leclercq B, Beier DR, Yu AS, Nigam SK: Developmentally regulated expression of organic ion transporters NKT (OAT1),OCT1, NLT (OAT2), and Roct. AmJ Physiol Renal Physiol 278: F635-F643, 2000
95. Sweet DH, Eraly SA, Vaughn DA, Bush KT, Nigam SK: Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models. Kidney Int 69: 837-845, 2006
96. Sweeney DE, Vallon V, Rieg T, Wu W, Gallegos TF, Nigam SK: Functional maturation of drug transporters in the developing, neonatal, and postnatal kidney. Mol Pharmacol 80: 147-154, 2011
97. Hirsch GH, Hook JB: Maturation of renal organic acid transport: Substrate stimulation by penicillin and p-aminohippurate (PAH). J Pharmacol Exp Ther 171: 103-108, 1970
98. Hook JB, Hewitt WR: Development of mechanisms for drug excretion. Am J Med 62: 497-506, 1977
99. Joseph S, Nicolson TJ, Hammons G, Word B, Green-Knox B, Lyn-Cook B: Expression of drug transporters in human kidney: Impact of sex, age, and ethnicity. Biol Sex Differ 6: 4, 2015
100. McLean AJ, Le Couteur DG: Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56: 163-184, 2004
101. Deguchi T, Ohtsuki S, Otagiri M, Takanaga H, Asaba H, Mori S, Terasaki T: Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 61: 1760-1768, 2002
102. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438: 137-142, 2002
103. Goldstein RS, Smith PF, Tarloff JB, Contardi L, Rush GF, Hook JB: Biochemical mechanisms of cephaloridine nephrotoxicity. Life Sci 42: 1809-1816, 1988
104. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W: Tenofovir renal proximal tubular toxicity is regulated byOAT1 and MRP4 transporters. Lab Invest 91: 852-858, 2011
105. Kone BC: The metabolic basis of solute transport. In: Brenner and Rector’s The Kidney, 7th Ed., edited by Brenner BM, Philadelphia, Saunders, 2004, pp 231-260
106. Ruegg CE, Mandel LJ: Bulk isolation of renal PCT and PST. II. Differential responses to anoxia or hypoxia. Am J Physiol 259: F176-F185, 1990
107. Cropp CD, Komori T, Shima JE, Urban TJ, Yee SW, More SS, Giacomini KM: Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 73: 1151-1158, 2008
108. Zhou F, Illsley NP, You G: Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells. Eur J Pharm Sci 27: 518-523, 2006
109. Kaler G, Truong DM, Sweeney DE, Logan DW, Nagle M, Wu W, Eraly SA, Nigam SK: Olfactorymucosa-expressed organic anion transporter, Oat6, manifests high affinity interactions with odorant organic anions. Biochem Biophys Res Commun 351: 872-876, 2006
110. Shiraya K, Hirata T, Hatano R, Nagamori S, Wiriyasermkul P, Jutabha P, Matsubara M, Muto S, Tanaka H, Asano S, Anzai N, Endou H, Yamada A, Sakurai H, Kanai Y: A novel transporter of SLC22 family specifically transports prostaglandins and co-localizes with 15-hydroxyprostaglandin dehydrogenase in renal proximal tubules. J Biol Chem 285: 22141-22151, 2010
111. Zhang Q, Hong M, Duan P, Pan Z, Ma J, You G: Organic anion transporter OAT1 undergoes constitutive and protein kinase C-regulated trafficking through a dynamin-and clathrindependent pathway. J Biol Chem283: 32570-32579, 2008
112. Wu W, Bush KT, Liu HC, Zhu C, Abagyan R, Nigam SK: Shared ligands between organic anion transporters (Oat1 and Oat6) and odorant receptors. Drug Metab Dispos 43: 1-9, 2015
113. Zhu C, Nigam KB, Date RC, Springer SA, Bush KT, Saier MH Jr, Wu W, Nigam SK: Evolutionary analysis and classification of OATs, OCTs, OCTNs and other SLC22 transporters: Structurefunction implications and analysis of sequence motifs. PLoS One 2015, in press